Tobira reports first Phase IIb data for HIV compound

Tobira Therapeutics Inc. (San Francisco, Calif.) said once-daily cenicriviroc plus Truvada emtricitabine/tenofovir from Gilead Sciences Inc. (NASDAQ:GILD) met the primary endpoint in the Phase IIb (Study 202) trial to treat HIV. Cenicriviroc plus Truvada led to a similar proportion of patients achieving undetectable viral load at week 24 vs. Sustiva efavirenz from Bristol-Myers Squibb Co. (NYSE:BMY) plus Truvada. Tobira said the primary endpoint was not powered to show either superiority or non-inferiority and that "the goal was to see similar numbers on the endpoint in all 3 arms." Tobira expects to present additional data this half. The trial enrolled 143 treatment-naïve patients with CCR-5-tropic HIV-1 infection. ...